Aleglitazar

Aleglitazar
Names
	IUPAC name (2S)-2-methoxy-3-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-7-benzothiophenyl]propanoic acid
	Other names Ro-0728804, R-1439
Identifiers
CAS Number	475479-34-6 ;
3D model (JSmol)	Interactive image; Interactive image;
ChEMBL	ChEMBL519504 ;
ChemSpider	8450255 ;
DrugBank	DB08483 ;
ECHA InfoCard	100.220.523
IUPHAR/BPS	7405;
KEGG	D08845 ;
PubChem CID	10274777;
UNII	41T4OAG59U ;
CompTox Dashboard (EPA)	DTXSID70197193 ;
	InChI InChI=1S/C24H23NO5S/c1-15-19(25-23(30-15)16-6-4-3-5-7-16)10-12-29-20-9-8-17(14-21(28-2)24(26)27)22-18(20)11-13-31-22/h3-9,11,13,21H,10,12,14H2,1-2H3,(H,26,27)/t21-/m0/s1 Key: DAYKLWSKQJBGCS-NRFANRHFSA-N ; InChI=1/C24H23NO5S/c1-15-19(25-23(30-15)16-6-4-3-5-7-16)10-12-29-20-9-8-17(14-21(28-2)24(26)27)22-18(20)11-13-31-22/h3-9,11,13,21H,10,12,14H2,1-2H3,(H,26,27)/t21-/m0/s1 Key: DAYKLWSKQJBGCS-NRFANRHFBF;
	SMILES CC1=C(CCOc2ccc(C[C@H](OC)C(O[H])=O)c3c2C=CS3)N=C(c4ccccc4)O1; O=C(O)[C@@H](OC)Cc4ccc(OCCc1nc(oc1C)c2ccccc2)c3c4scc3;
Properties
Chemical formula	C24H23NO5S
Molar mass	437.51 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
	verify (what is ?)
	Infobox references

Aleglitazar is a peroxisome proliferator-activated receptor agonist (hence a PPAR modulator ) with affinity to PPARα and PPARγ, which was under development by Hoffmann–La Roche for the treatment of type II diabetes.[1] It is no longer in phase III clinical trials.[2]

References

"Statement on a nonproprietary name adopted by the USAN Council: Aleglitazar" (PDF). United States Adopted Names. American Medical Association. Retrieved 2008-08-17.
"Roche halts diabetes drug trial in blow to pipeline". Roche. Retrieved 2013-07-10.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[url-1] "Statement on a nonproprietary name adopted by the USAN Council: Aleglitazar" (PDF). United States Adopted Names. American Medical Association. Retrieved 2008-08-17.

[Roche_halts_diabetes_drug_trial_in_blow_to_pipeline-2] "Roche halts diabetes drug trial in blow to pipeline". Roche. Retrieved 2013-07-10.

PPAR modulators
PPARα	Agonists: 15-HETE 15-HpETE Aleglitazar Aluminium clofibrate Arachidonic acid Bezafibrate Clofibrate CP-775146 Daidzein DHEA (prasterone) (in rodents) Elafibranor Etomoxir Fenofibrate Genistein Gemfibrozil GW-7647 Lanifibranor Leukotriene B₄ LG-101506 LG-100754 Lobeglitazone Muraglitazar Oleylethanolamide Palmitoylethanolamide Pemafibrate Perfluorononanoic acid Perfluorooctanoic acid Pioglitazone Saroglitazar Sodelglitazar Tesaglitazar Tetradecylthioacetic acid Troglitazone WY-14643 Antagonists: GW-6471 MK-886
PPARδ	Agonists: 15-HETE 15-HpETE Arachidonic acid Bezafibrate Daidzein Elafibranor Fonadelpar Genistein GW-0742 GW-501516 L-165,041 Lanifibranor LG-101506 Seladelpar Sodelglitazar Tetradecylthioacetic acid Antagonists: FH-535 GSK-0660 GSK-3787
PPARγ	Agonists: 5-Oxo-ETE 5-Oxo-15-hydroxy-ETE 15-Deoxy-Δ^12,14-prostaglandin J₂ 15-HETE 15-HpETE Aleglitazar Arachidonic acid Balaglitazone Berberine Bezafibrate Cannabidiol Cevoglitazar Ciglitazone Daidzein Darglitazone Edaglitazone Efatutazone Englitazone Etalocib Farglitazar Genistein GW-1929 Ibuprofen Imiglitazar Indeglitazar Lanifibranor LG-100268 LG-100754 LG-101506 Lobeglitazone Muraglitazar (muroglitazar) nTZDpa Naveglitazar Netoglitazone Oxeglitazar Peliglitazar Pemaglitazar Perfluorononanoic acid Pioglitazone Prostaglandin J₂ Ragaglitazar Reglitazar Rivoglitazone Rosiglitazone RS5444 Saroglitazar Sipoglitazar Sodelglitazar Telmisartan Tesaglitazar Troglitazone SPPARMs: BADGE EPI-001 INT-131 MK-0533 S26948 Antagonists: FH-535 GW-9662 SR-202 T-0070907 Unknown: SR-1664
Non-selective	Agonists: Ciprofibrate Clinofibrate Clofibride Englitazone Etofibrate Farglitazar Netoglitazone Ronifibrate Rivoglitazone Simfibrate
See also Receptor/signaling modulators Nuclear receptor modulators